Paxlovid Failed to Ease Long COVID Symptoms in Trial
A large-scale study found no symptom relief for adults with Long COVID who took the antiviral medication.
Updated on Oct. 7, 2026 in COVID-19
Live Poll
Does medical research on Long COVID provide enough benefit to patients to justify the cost?
A clinical trial published August 31, 2026, in Lancet Infectious Diseases found that Paxlovid did not improve symptoms for adults with Long COVID. The study monitored 959 participants across the United States to determine if the drug used for acute infection could provide a benefit for lingering symptoms.
Why it matters
This study addressed the urgent need for effective Long COVID treatments by testing if existing antivirals could reduce the burden of persistent symptoms. The findings clarify that, for this population, the standard antiviral regimen does not offer the hoped-for recovery benefit.
In a randomized clinical trial of 959 adults across 69 U.S. sites, researchers found that participants receiving Paxlovid improved at the same rate as those receiving a placebo over a 25-day treatment regimen. This study marks a significant effort to evaluate antiviral efficacy in chronic cases.
The players
Lancet Infectious Diseases
A peer-reviewed medical journal that publishes original research on the prevention, diagnosis, and treatment of infectious diseases.
The details
Researchers organized participants into three cohorts focused on cognitive issues, blood pressure regulation, and exercise intolerance. Participants were randomly assigned to receive either the antiviral treatment or a placebo to observe if the medication could mitigate specific underlying symptoms. The trial concluded that the drug was well tolerated, though it provided no statistically significant improvement in recovery outcomes compared to the control group.
Timeline
Data collection for the clinical trial began in July 2023.
Data collection for the clinical trial concluded in March 2025.
Study results were published in Lancet Infectious Diseases on August 31, 2026.
Health Landscape
This trial follows the trajectory of the RECOVER Initiative, which seeks to identify effective treatments for the complex and lingering effects of COVID-19. It confirms that repurposed antivirals do not serve as a universal solution for the varied symptoms defining the condition.
If you are managing Long COVID, these findings suggest that Paxlovid is not a current standard treatment for your symptoms. Discuss your specific concerns with your physician, as care strategies should remain focused on addressing individual symptoms through evidence-based supportive care.
The takeaway
While this antiviral treatment did not show efficacy in this trial, the study provides critical clarity for the medical community. Patients should continue to track symptom patterns and consult with a primary care physician to discuss new and emerging approaches to symptom management.
What happens next
The research team plans to release additional findings and results from the analysis of patient blood samples in future reports.
Further reading
For more on ongoing research and management strategies, visit the COVID-19 section.
Source note: This article includes information reported by National Institutes of Health (NIH).
Live Poll
Does medical research on Long COVID provide enough benefit to patients to justify the cost?
